Rapid-SF: A Rapid Whole-Blood Screen for Soluble Fibrin Monomer^[*]

Summary

Thrombosis accounts for a high proportion of disability and death in the West. Although soluble fibrin (SF) assays have been shown to be good predictors of thrombosis, current quantitative assays are too complex or lengthy to provide timely results, while simpler methods are qualitative and lack sensitivity. We here describe a rapid, new, protamine-based whole-blood screening method for SF which is quantitative and suitable for point-of-care use. Citrated whole blood is mixed with reagent under controlled conditions and the time until development of an SF precipitate is measured. Negative samples remain precipitate-free for 300 seconds. Strongly positive samples develop precipitate in as little as 10 seconds. SF times are mathematically converted to arbitrary SF units (SFU). This Rapid-SF test provides a simple and reliable means of detecting the presence of SF, and is well-suited for whole-blood rapid screening in the emergency department, operating room or clinic.

Keywords

Disseminated intravascular coagulation - fibrin-analysis - thrombosis diagnosis - soluble fibrin - paracoagulation

^* Funded in part by a grant from the Montgomery Street Foundation

• References

• 1 Bakker CM, Knot EA, Stibbe J, Wilson JH. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992; 15: 330-5.
• 2 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Morrat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74 (03) 833-6.
• 3 Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost 1999; 82: 673-83.
• 4 Caliezi C, Fhnfsinn N, Mauron T, Baumgartner I, Sulzer I, Ulrich M, Cottier C, Biasiutti FD, Lämmle B, Wuillemin WA. Performance of a new fibrin monomer assay to exclude deep vein thrombosis in symptomatic outpatients. Thromb Haemost 1999; 81: 50-3.
• 5 Halvorsen S, Skjønsberg Ruyter R, Godal HC. Comparison of methods for detecting soluble fibrin in plasma. An in vitro study. Thromb Res 1990; 57: 489-97.
• 6 Wieding JU, Eisinger G, Køstering H. Determination of soluble fibrin by turbidimetry of its protamine sulfate-induced paracoagulation. J Clin Chem Clin Biochem 1989; 27: 57-63.
• 7 Wieding JU, Hosius C. Determination of soluble fibrin: A comparison of four different methods. Thromb Res 1992; 65: 745-56.
• 8 Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyma K, Nagaya S, Deguchi H, Mori Y, Kaneko T, Deguchi K, Fujii J, Shiku H. Increased plasmasoluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51: 255-60.
• 9 Nieuwenhuizen W, Hoegee-De Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost 1992; 68 (03) 273-7.
• 10 Bredbacka S, Blombäck M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesth Scand 1993; 37: 125-30.
• 11 Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost 1995; 74 (02) 673-9.
• 12 Bos R, Laterveer-Vreeswijk GH, Lockwood D, Szewczyk K, Nieuwenhuizen W. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders. Thromb Haemost 1999; 81: 54-9.
• 13 Wada H, Sakuragawa N, Mori Y, Takagi M, Nakasaki T, Shimura M, Hiyoyama K, Nisikawa M, Gabazza EC, Deguchi K, Kazama M, Shiku H. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999; 60: 273-8.
• 14 Bredbacka S, Blombäck M, Wiman B. Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am J Hematol 1994; 46: 289-94.
• 15 Brosstad F, Kierulf P, Godal HC. The fibrin-solubilizing effect of fibrinogen as studied by light scattering. Thromb Res 1979; 14: 705-12.
• 16 Usero JL, Burguillo FJ, Izquierdo C, Del-Arco A, Herraez MA. The fibrinogen-fibrin complex: stoichiometry and negative cooperativity. Thromb Res 1985; 39: 379-86.
• 17 Siegal S, Castellan Jr NJ. Nonparametric statistics for the Behavioral Sciences. 2nd edition.. New York: McGraw Hill Book Company; 1988: 137-43.
• 18 Royston P. Approximating the Shapiro-Wilk W test for non-normality. Stat Comput 1992; 02: 117-9.
• 19 Siegal S, Castellan Jr NJ. Nonparametric statistics for the Behavioral Sciences. 2nd edition.. New York: McGraw Hill Book Company; 1988: 144-51.
• 20 Siegal S, Castellan Jr NJ. Nonparametric statistics for the Behavioral Sciences. 2nd edition.. New York: McGraw Hill Book Company; 1988: 128-37.
• 21 Siegal S, Castellan Jr NJ. Nonparametric statistics for the Behavioral Sciences. 2nd edition.. New York: McGraw Hill Book Company; 1988: 103-11.
• 22 Siegal S, Castellan Jr NJ. Nonparametric statistics for the Behavioral Sciences. 2nd edition.. New York: McGraw Hill Book Company; 1988: 235-44.
• 23 Wiltzius P, Dietler G, Kanzig W, Hofmann V, Haberli A, Straub PW. Fibrin aggregation before sol-gel transition. Biophys J 1982; 38: 123-32.
• 24 Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation: the role of the fibrinogen-fibrin monomer complex. Thromb Haemost 1976; 31: 36-48.
• 25 Horn RG, Hawiger J, Collins RD. Electron Microscopy of fibrin-like precipitate formed during the paracoagulation reaction between soluble fibrin monomer complexes and protamine sulphate. Br J Haematol 1969; 17: 463-6.
• 26 Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ 1998; 316: 984-7.
• 27 Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Tech Rep Ser. 1998; 877: 1-89.
• 28 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre casecontrol study. Lancet 1995; 346: 1575-82.
• 29 Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-7.
• 30 Lapostolle F, Surget V, Borron SW, Desmaizières M, Sordelet D, Lapandry C, Cupa M, Adnet F. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345: 779-83.